UNSPSC 51112000: Tyrosine kinase inhibitors

This classification denotes a protein-tyrosine kinase family that was originally identified by homology to the rous sarcoma virus oncogene protein pp60(v-src). they interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways. oncogenic forms of src-family kinases can occur through altered regulation or expression of the endogenous protein and by virally encoded src (v-src) genes.

UNSPSC 51112000 Tyrosine kinase inhibitors is a Class code covering generic multi-source pharmaceuticals and over-the-counter products procured by state and local health systems, government facilities, and cooperative purchasing alliances. State and local governments use this code to source finished pharmaceutical products for distribution through authorized wholesalers to hospitals, clinics, correctional facilities, and other public health settings. The work involves manufacturers submitting detailed product specifications (National Drug Codes, SKUs, UPCs, strength, dosage form, packaging configurations, and manufacturing locations), certifying cGMP and Drug Supply Chain Security Act compliance, maintaining relationships with authorized wholesalers with chargeback capability, and offering flexible pricing structures such as flat price, net price formats, or WAC-minus arrangements. Issuing bodies include state departments of administration, multistate cooperative purchasing alliances, and participating member jurisdictions across multiple states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, with a response date of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across Minnesota, Oregon, and other participating member facilities. MMCAP requires vendors to supply products through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with awarded vendors to be provided to wholesalers by May 15, 2026, and contract effectiveness on July 1, 2026. Evaluation is weighted heavily toward price competitiveness (75 percent), with secondary criteria including fixed pricing (10 percent), EDI capability (5 percent), compliance with administrative data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, and all products must have expiration dates of at least one year from manufacture with a minimum six-month shelf life. The contract term is two years for new vendors with optional extensions, while incumbent amendments extend through June 30, 2028.